Colorectal cancer (CRC) is one of the most common malignancies in the United States. Every
3 years, the American Cancer Society provides an update of CRC incidence, survival, and …

Background Regorafenib confers an overall survival benefit in patients with refractory metastatic
colorectal cancer; however, the adverse event profile of regorafenib has limited its use. …

Background Inadequate understanding of interpretation of quality of life (QoL) instruments
leads to unsatisfactory data reporting and clinical decision-making, including in gastric cancer …

BACKGROUND Screening for colorectal cancer (CRC) has been successful in decreasing
the incidence and mortality from CRC. Although new screening tests have become available, …

Objectives Liposomal irinotecan (nal-IRI) is a topoisomerase inhibitor proven to improve
survival in metastatic pancreatic cancer (mPC). This study describes real-world characteristics …

Worldwide, colorectal cancer has a higher incidence rate in men than in women, suggesting
a protective role for sex hormones in the development of the disease. Preclinical data …

Epstein-Barr virus associated gastric cancer (EBVaGC) comprises approximately 10% of
gastric carcinomas. Multiple factors contribute to tumorigenesis, including EBV driven …

Background: Colorectal cancer is the second leading cause of cancer death in the United
States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. …

The myelodysplastic syndromes (MDS) are clonal bone marrow disorders that lead to
underproduction of normal blood cells. The consequent cytopenias result in infections and …

Purpose: GEP-NENs are rare malignancies with increasing incidence. Their molecular
characteristics are still undefined. We explored the underlying biology of GEP-NENs and the …